Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...

The presentation of Japanese drugmaker Takeda’s latest financial results were presented Thursday, though they took a back ...

Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...

Weber, one of the highest-profile foreign CEOs in Japan, spearheaded Takeda's $59 billion takeover of British-founded Shire ...

DelveInsight's Inflammatory Bowel disease market Report provides comprehensive insights into the epidemiology and market dynamics across the 7MM. LAS VEGAS , NV, UNITED STATES, January 30, 2025 ...

Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences Limited and Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502/NYSE:TAK), celebrates the ...

Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.

Takeda (TAK) stock rose in premarket trading after raising its full-year outlook and appointing Julie Kim as the next CEO.

Weber said it is the right time to appoint a successor given "our competitive growth outlook, new product launches expected ...

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...

Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...

The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...